The European functional foods market earned $545 million in 2008 and is estimated to earn up to $2 billion in 2014, according to analysis from Frost & Sullivan (Palo Alto, CA), the company reported on January 13.
The European functional foods market earned $545 million in 2008 and is estimated to earn up to $2 billion in 2014, according to analysis from Frost & Sullivan (Palo Alto, CA), the company reported on January 13.
"A variety of ingredients positioned for heart-health, with their functional benefits, is increasingly used for the fortification of various food and beverage applications," said Frost & Sullivan research analyst Chandrasekhar S. "The preventive cost of cardiovascular disease (CVD) by virtue of these ingredients is much cheaper for the consumers than the cost of its treatment."
Nevertheless, the heart health ingredients market is restrained by a 2000 EU food-labeling directive preventing health claims from being made on products.
Nonetheless, European manufacturers have submitted their dossiers to the European Food Safety Authority (EFSA; Parma, Italy) to place health claims on their ingredients.
"Manufacturers, with the help of industry associations such as GOED (Salt Lake City) are lobbying for the usage of health claims," noted Chandrasekhar.
"They are also involved in extensive branding and promotional activities to increase consumer awareness on CVD and the positive impact of the various ingredients, thereby enhancing the credibility of such awareness campaigns."
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.